| Project/Area Number |
09671277
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
SUZUKI Masanori Tohoku Univ.hospital, Research Associate, 医学部・附属病院, 助手 (70206530)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ENDO Kojin Tohoku Univ.hospital, Research Associate, 医学部・附属病院, 助手 (70292315)
UNNO Michiaki Tohoku Univ.School of Med., Research Associate, 医学部, 助手 (70282043)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 1998: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 1997: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | BiPe duct cancer / Adoptive immunotherapy / MUC-1 / MUSE II / SEA / scFu / SEA D227 / MUSE 11 / CTL / LAK / MUC-1 / バイスペシフィック抗体 |
|---|
| Research Abstract |
A SEA-antibody single chain Fv (SEA-scFv) fusion protein was produced byu bacterial expression system in this study. SEA-scFv has both staphylococcal enterotoxin A(SEA) effects and antibody activity directed at the epithelial mucin core protein MUCl, a cancer associated antigen. It was expressed mostly in the cytoplasm as an insoluble form. The gene product was solubilized by guanidine hydrochloride, refolded by conventional dilution method, and purified using metal-chelating chromatography. The resulting SEA-scFv fusion protein preparation was found to react with MUC1 and MHC class II antigens and had the ability to enhance cytotoxicity of lymphokine activated killer cells with a T cell phenotype against a human bile duct carcinoma cell line, TFK- 1, expressing MUC1. This genetically engineered SEA-scFv fusion protein promises to be an important reagent for cancer immunotherapy.
|
